GlassScriptPhysician profile
Hitesh Patel
NPI 1871534305
$3,303.78
in general payments reported to CMS, 2019-2025
27 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.24 · 2020: $217 · 2021: $458 · 2022: $619 · 2023: $621 · 2024: $764 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.30 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $375.66 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $359.60 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $313.40 | 2021-2025 | Cequa |
| Glaxosmithkline, LLC. | $302.44 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $190.49 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $162.84 | 2020-2025 | |
| Amgen INC. | $133.58 | 2020-2025 | Otezla, Repatha, Repatha |
| Biotissue Holdings INC. | $122.28 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.50 | 2022-2025 | Jardiance |
| Abbott Laboratories | $113.55 | 2024 | Freestyle Libre 3 |
| Djo, LLC | $97.13 | 2024 | Cmf |
| Kala Pharmaceuticals, INC. | $83.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.20 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $60.72 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.64 | 2023-2024 | Rexulti |
| Ge Healthcare | $27.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $27.82 | 2025 | |
| Merck Sharp & Dohme LLC | $27.33 | 2020 | |
| Genentech USA, INC. | $26.81 | 2020-2022 | |
| Exact Sciences Corporation | $24.34 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $23.45 | 2025 | Aptima |
| Dexcom, INC. | $15.92 | 2024 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $15.83 | 2024 | Isturisa, Signifor Lar |
| Daiichi Sankyo INC. | $14.99 | 2021 | |
| Allergan, INC. | $14.94 | 2020 | |
| Althera Pharmaceuticals LLC | $8.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hitesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.